Galectin Therapeutics Inc (NASDAQ: GALT) is 62.35% higher on its value in year-to-date trading and has touched a low of $1.55 and a high of $4.27 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The GALT stock was last observed hovering at around $2.74 in the last trading session, with the day’s loss setting it -0.05%.
Currently trading at $2.69, the stock is 17.24% and 15.13% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.19 million and changing -1.64% at the moment leaves the stock 15.03% off its SMA200. GALT registered 56.69% gain for a year compared to 6-month gain of 39.64%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 20.58% loss in the last 1 month and extending the period to 3 months gives it a -0.92%, and is 16.67% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 9.87% over the week and 7.37% over the month.
Galectin Therapeutics Inc (GALT) has around 14 employees, a market worth around $167.84M and $0.00M in sales. Distance from 52-week low is 73.31% and -36.86% from its 52-week high. The company has generated returns on investments over the last 12 months (-393.95%).
The EPS is expected to shrink by -6.76% this year.
Galectin Therapeutics Inc (GALT) Top Institutional Holders
91.0 institutions hold shares in Galectin Therapeutics Inc (GALT), with institutional investors hold 21.98% of the company’s shares. The shares outstanding are 61.85M, and float is at 43.23M with Short Float at 11.60%. Institutions hold 15.17% of the Float.
The top institutional shareholder in the company is VANGUARD GROUP INC with over 2.12 million shares valued at $4.78 million. The investor’s holdings represent 3.4143% of the GALT Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 1.56 million shares valued at $$3.53 million to account for 2.5232 of the shares outstanding. The other top investors are ADVISOR GROUP HOLDINGS, INC. which holds 1.13 million shares representing 1.8168% and valued at over $2.54 million, while SUSQUEHANNA INTERNATIONAL GROUP, LLP holds 1.5621 of the shares totaling 0.97 million with a market value of $2.19 million.
Galectin Therapeutics Inc (GALT) Insider Activity
The most recent transaction is an insider purchase by Zordani Richard A. Jr.,the company’sDirector. SEC filings show that Zordani Richard A. Jr. bought 1,759 shares of the company’s common stock on Aug 23 ’24 at a price of $2.30 per share for a total of $4046.0. Following the purchase, the insider now owns 32083.0 shares.
Galectin Therapeutics Inc disclosed in a document filed with the SEC on Aug 23 ’24 that Zordani Richard A. Jr. (Director) bought a total of 1,000 shares of the company’s common stock. The trade occurred on Aug 23 ’24 and was made at $2.30 per share for $2300.0. Following the transaction, the insider now directly holds 2000.0 shares of the GALT stock.
Still, SEC filings show that on Aug 22 ’24, Zordani Richard A. Jr. (Director) acquired 741 shares at an average price of $2.30 for $1704.0. The insider now directly holds 30,324 shares of Galectin Therapeutics Inc (GALT).
